source
- Novartis licenses Abogen’s mRNA CD19×CD3 engager in $575M upfront dealAbogen Biosciences saw its COVID vaccine miss the market, prompting questions about whether its mRNA platform could be leveraged for other therapies. Novartis agreed to pay $575 million up front f…
- Viatris to acquire Pacira BioSciences for $1.65 billion to expand non‑opioid pain portfolioViatris announced a $1.65 billion acquisition of Pacira BioSciences, aiming to broaden its non‑opioid pain‑relief offerings. The deal includes Pacira's marketed products Exparel and Zilretta, which…